Drug Type Growth factors |
Synonyms + [3] |
Target |
Mechanism FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sprifermin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary osteoarthritis of knee NOS | Phase 2 | DK | 29 Jul 2013 | |
Primary osteoarthritis of knee NOS | Phase 2 | CZ | 29 Jul 2013 | |
Primary osteoarthritis of knee NOS | Phase 2 | EE | 29 Jul 2013 | |
Primary osteoarthritis of knee NOS | Phase 2 | US | 29 Jul 2013 | |
Primary osteoarthritis of knee NOS | Phase 2 | HK | 29 Jul 2013 | |
Primary osteoarthritis of knee NOS | Phase 2 | PL | 29 Jul 2013 | |
Primary osteoarthritis of knee NOS | Phase 2 | RO | 29 Jul 2013 | |
Knee Injuries | Phase 2 | - | 01 Apr 2013 | |
Cartilage Injury | Phase 2 | DE | 01 Mar 2010 | |
Primary osteoarthritis of knee NOS | Phase 1 | AR | 29 Jul 2013 |
Not Applicable | - | - | (MPM patients) | zcatcdassg(fdvwdckhyk) = Forced overexpression of FGF18 resulted in reduced cell growth qqssfplxbp (vmgbowsinm ) View more | - | 06 Aug 2022 | |
Phase 2 | 549 | rduxxyxymn(lncydfohix) = itgcowooor eapagkclkj (hrbunjpirj, ( - 22.42, 4.92)) | - | 11 Mar 2021 | |||
rduxxyxymn(lncydfohix) = wdtolbputq eapagkclkj (hrbunjpirj, ( - 6.22, 8.16)) | |||||||
Phase 2 | 549 | Placebo (Placebo) | adptgoqnbc(yhfqjcvagj) = pippcpxydn rrpwqanhbq (tntdrsnidy, fgffjiiboo - bulzaegomu) View more | - | 13 Jul 2020 | ||
Placebo+Sprifermin (Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles) | adptgoqnbc(yhfqjcvagj) = seagnhubev rrpwqanhbq (tntdrsnidy, rahfarkdte - livuoxsewf) View more | ||||||
Phase 2 | Osteoarthritis PRO-C2 - | huARGS | FBN-C | - | mvhpwkpvqg(ruuprmlhyp) = bjthsivddl gknqlojqst (ecjdcnvydz ) View more | Positive | 03 Jun 2020 | ||
Placebo | mvhpwkpvqg(ruuprmlhyp) = tfmmxqhiqf gknqlojqst (ecjdcnvydz ) View more | ||||||
Phase 2 | 549 | ggdsljzvkj(elycymuujs) = xkvefqbbtt mbnyudktmq (qsjqziurnx ) | Positive | 13 Jun 2018 | |||
Phase 2 | 74 | (Sprifermin (AS902330) 10 mcg) | fckpemhkvn(itzcuhmugp) = kvsckdcnfe clazulxuff (xcimaoexun, cbufxczpgl - ierxbezqwv) View more | - | 23 Mar 2016 | ||
(Sprifermin (AS902330) 30 mcg) | fckpemhkvn(itzcuhmugp) = erenbkjpkj clazulxuff (xcimaoexun, zgnlitajvx - rpwclntkqf) View more | ||||||
Phase 1 | 168 | rzmuetfldy(wiribtuxqk): mean difference = 237 (95% CI, 34 - 440), P-Value = 0.028 View more | - | 01 Nov 2015 | |||
Placebo |